Odwala a melanoma amatha kupewa maopaleshoni osafunikira komanso zovuta

Lero, SkylineDx yalengeza kuti mayeso awo a Merlin kwa odwala melanoma akanatha kuchepetsa 59% ya zovuta zobwera chifukwa cha opaleshoni pochotsa kusankha odwala ochitidwa opaleshoni. Mayeso a Merlin omwe amapezeka pamalonda amazindikiritsa odwala omwe ali ndi khansa ya melanoma omwe amatha kusiya opaleshoni ya sentinel lymph node biopsy (SLNB), njira yomwe imagwiritsidwa ntchito kudziwa kufalikira kwa khansayo potengera zolinga. Pafupifupi 80% ya odwala biopsy imabwereranso kukhala yopanda metastasis ndipo ikadatha kupewedwa. Merlin amalankhula za vuto lofunika lachipatala lomwe silinakwaniritsidwe pozindikira odwalawa omwe ali ndi chiopsezo chochepa cha metastasis pa matenda ndipo motero sangachepetse maopaleshoni osafunika komanso zovuta zomwe zimagwirizanitsidwa nazo. Zotsatira zasindikizidwa mu nyuzipepala yowunikiridwa ndi anzawo komanso yasayansi, International Journal of Dermatology.

Olembawo adafufuza kuchuluka kwa zovuta zomwe zimagwirizanitsidwa ndi njira ya SLNB. Kwa odwala onse a 558, zolemba zamankhwala zamagetsi zidafufuzidwa kuti zizindikire zovuta zokhudzana ndi opaleshoni. Zambiri zawo zikuwonetsa kuti zovuta zokhudzana ndi SLNB ndizofala kwambiri popeza 17.4% idayambitsa vuto limodzi. Zovuta zofala kwambiri zinali seroma (9.3%), matenda / cellulitis (4.8%) ndi lymphedema (4.3%). Komanso, odwala asanu ndi mmodzi (1.1%) adapempha thandizo kuchipatala chachipatala mkati mwa masiku 30 atachitidwa opaleshoni ndipo odwala asanu ndi anayi (1.6%) adalandiridwanso kuchipatala mkati mwa masiku 30 atachitidwa opaleshoni. Mwa odwala 558, 279 (51%) anali ndi zotsatira za Merlin Test Low-Risk. Kupanda opaleshoni ya SLNB mwa odwala 279 kukanachepetsa zovuta ndi 59.2%, mgululi.